Dr. Reddy's Laboratories SA
June 16, 2025
Company Presentation
Oncology
Dr. Reddy's Laboratories Ltd (Dr. Reddy's), is an integrated global pharmaceutical company serving +800 million patients globally across 76 countries across US, Europe and Emerging markets. Dr. Reddy's mission is to serve customers worldwide, providing access to affordable and innovative medicines. The company's primary activities include the development, manufacturing and commercialization of prescription drugs within Oncology, Hematology, Immunology, CVM; GI and dermatology therapeutic areas. Dr. Reddy's pipeline includes New Chemical Entities (NCEs) and New Biological Entities (NBEs) that focus on the treatment of cancer with 23 assets in preclinical and clinical development..
As of October 1st 2024. Dr. Reddy's has launched a global consumer health business with headquarter in Switzerland based on the acquisition of the Nicotine Replacement Therapy (“NRT”) portfolio.
Company HQ City:
Basel
Company HQ State:
Basel
Company HQ Country:
Switzerland
Year Founded:
1984
Lead Product in Development:
1. CA170 VISTA antagonism in NSCLC / in Phase III
2. AUR103 CD47 inhibitor In Leukemia / in Phase II
3. AUR106 Tigit inhibitor in multiple oncological indications / in Phase I
4. AUR108 DHODH inhibitor in Leukemia/ / in Phase I
5. AUR109 DDR1/SIK2 kinase inhibitor in ovarian cancer / in Phase II
6. COYA 30 an investigational drug combination of low-dose IL-2 and CTLA4-Ig (abatacept). for the treatment of Amyotrophic Lateral Sclerosis (ALS) in partnership with Coya Therapeutics
In addition to a rich biosimilar portfolio.
CEO
Erez Israeli
Development Phase of Lead Product
Multiple Products in Market
Number of Unlicensed Products Looking for Licensing
23
Exchange
New York Stock Exchange (NYSE) (ADR listed)
National Stock Exchange (NSE)
Bombay Stock Exchange (BSE)
NSE IFSC Limited (NIL)
Ticker
Bombay Stock Exchange (BSE) 500124
National Stock Exchange (NSE) DRREDDY-EQ
New York Stock Exchange (NYSE) RDY
NSE IFSC Limited DRREDDY
Reuters REDY.NS
Bloomberg DRRD:IN
International Securities Identification Number (ISIN) INE 089A01023
CUSIP number 256135203
When you expect your next catalyst update?
Launch of Biosimilar portfolio and in-licensed NCEs/NBEs.
What is your next catalyst (value inflection) update?
2026
Primary Speaker
SVP, Head of external ecosystem collaboration and partnership, Innovation
Dr. Reddy's Laboratories SA
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}